QUOTE AND NEWS
Motley Fool  Jan 14  Comment 
Ziopharm shares have soared over 50%, while Intrexon is up over 20%. What has investors so excited?
Benzinga  Jan 14  Comment 
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) shares jumped 54.53% to $8.87 following announcement of licensing agreement with University of Texas MD Anderson Cancer Center. Smith Micro Software Inc. (NASDAQ: SMSI) shares surged 11.11% to $1.40 after...
TheStreet.com  Dec 29  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.  TheStreet Ratings quantitative algorithm...
Benzinga  Dec 3  Comment 
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the presentation...
SeekingAlpha  Sep 4  Comment 
By Mark Kroenke: Antibiotic resistance is a problem. There is no question that novel compounds are needed, and Congress has attempted to jump start development of new anti-infectives by passing the GAIN act which went into effect October 1st,...
SeekingAlpha  Jul 29  Comment 
By Michael Vascocu: There are still many big catalysts ahead and closer to the end of the year that will propel the stock price much higher Back in May, I wrote a very thorough article on the potential of the IL-12 therapy that Ziopharm...
SeekingAlpha  Jul 29  Comment 
By Mark Kroenke: During their June 25th presentation at the JMP Securities Healthcare Conference (audio file), Dr. Lewis and Dr. Lebel spent a good chunk of their time discussing "the power of the platform" and Ziopharm's (NASDAQ:ZIOP) budding...
FierceBiotech  Jul 22  Comment 
Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.
Benzinga  Jul 22  Comment 
ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction with...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki